Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. (NASDAQ: VKTX) announced on Monday that clinical data from the firm's VK2735 obesity program is being revealed in two poster presentations at ObesityWeek 2024 (3 – 6 Nov 2024), the annual meeting of the Obesity Society.

The product, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed for the potential treatment of various metabolic disorders. The company is assessing both subcutaneous and oral formulations of VK2735 in clinical trials.

One presentation is to summarise results from the firm's Phase two VENTURE clinical trial, which assessed 13 weeks of weekly treatment with a subcutaneous formulation of VK2735 in obese patients. A second presentation is to highlight results from the firm's Phase one multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days.